X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-11 | MLYS | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.00 | -5,026 | 140,991 | -3% | -$75,398 | |||||
| D | 2024-11-06 | MLYS | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.03 | -25,482 | 135,974 | -16% | -$383,066 | |||||
2024-10-11 | MLYS | Levy Adam Scott | CFO, Secretary | S - Sale | $13.57 | -10,757 | 236,854 | -4% | -$146,004 | ||||||
2024-10-11 | MLYS | Congleton Jon | CEO | S - Sale | $13.52 | -15,271 | 895,941 | -2% | -$206,433 | ||||||
2024-07-24 | MLYS | Slingsby Brian Taylor | Dir, 10% | S - Sale | $13.05 | -550,000 | 8,644,579 | -6% | -$7,177,500 | ||||||
| D | 2024-07-16 | MLYS | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.00 | -525 | 102,873 | -1% | -$7,876 | |||||
2024-07-11 | MLYS | Levy Adam Scott | CFO, Secretary | S - Sale | $13.14 | -10,757 | 247,611 | -4% | -$141,394 | ||||||
2024-07-11 | MLYS | Congleton Jon | CEO | S - Sale | $13.34 | -15,746 | 911,212 | -2% | -$210,075 | ||||||
| M | 2024-06-17 | MLYS | Congleton Jon | CEO | S - Sale | $12.01 | -49,313 | 926,958 | -5% | -$592,022 | |||||
| M | 2024-06-12 | MLYS | Congleton Jon | CEO | S - Sale | $12.70 | -72,797 | 976,271 | -7% | -$924,203 | |||||
2024-06-11 | MLYS | Levy Adam Scott | CFO, Secretary | S - Sale | $12.94 | -96,815 | 255,462 | -27% | -$1,252,718 | ||||||
| D | 2024-05-09 | MLYS | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.00 | -100 | 66,997 | 0% | -$1,500 | |||||
2024-02-12 | MLYS | Samsara Biocapital Gp, LLC | 10% | P - Purchase | $13.50 | +555,555 | 5,074,916 | +12% | +$7,499,993 | ||||||
2023-11-22 | MLYS | Congleton Jon | CEO | P - Purchase | $5.97 | +4,250 | 1,049,068 | 0% | +$25,356 | ||||||
2023-09-06 | MLYS | Congleton Jon | CEO | P - Purchase | $12.08 | +2,250 | 1,044,818 | 0% | +$27,180 | ||||||
2023-08-17 | MLYS | Congleton Jon | CEO | P - Purchase | $12.10 | +2,250 | 1,042,568 | 0% | +$27,225 | ||||||
| DM | 2023-08-10 | MLYS | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $12.92 | -231,716 | 0 | -100% | -$2,994,401 | |||||
2023-08-11 | MLYS | Congleton Jon | CEO | P - Purchase | $12.89 | +2,000 | 1,040,318 | 0% | +$25,780 | ||||||
| D | 2023-02-14 | MLYS | Hbm Healthcare Investments (Cayman) Ltd. | 10% | P - Purchase | $16.00 | +312,500 | 3,218,106 | +11% | +$5,000,000 | |||||
| D | 2023-02-14 | MLYS | Ra Capital Management, L.P. | Dir | P - Purchase | $16.00 | +1,250,000 | 1,311,247 | >999% | +$20,000,000 | |||||
2023-02-14 | MLYS | Levy Adam Scott | CFO, Chief Bus. Officer, Secy. | P - Purchase | $16.00 | +6,250 | 350,811 | +2% | +$100,000 | ||||||
| D | 2023-02-14 | MLYS | Akkaraju Srinivas | Dir, 10% | P - Purchase | $16.00 | +937,500 | 4,519,361 | +26% | +$15,000,000 | |||||
| D | 2023-02-14 | MLYS | Slingsby Brian Taylor | Dir, 10% | P - Purchase | $16.00 | +250,000 | 9,194,579 | +3% | +$4,000,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |